MX2009004054A - 1,5-difenil-3-bencilamino-1,5-dihidropirrolidin-2-ona como moduladores de receptor de cb1. - Google Patents

1,5-difenil-3-bencilamino-1,5-dihidropirrolidin-2-ona como moduladores de receptor de cb1.

Info

Publication number
MX2009004054A
MX2009004054A MX2009004054A MX2009004054A MX2009004054A MX 2009004054 A MX2009004054 A MX 2009004054A MX 2009004054 A MX2009004054 A MX 2009004054A MX 2009004054 A MX2009004054 A MX 2009004054A MX 2009004054 A MX2009004054 A MX 2009004054A
Authority
MX
Mexico
Prior art keywords
compounds
antipsychotics
blockade
schizophrenia
mammals
Prior art date
Application number
MX2009004054A
Other languages
English (en)
Spanish (es)
Inventor
David Scott Coffey
John Mehnert Schaus
Jingdan Hu
Stacy Jo Keding
Joseph Herman Krushinski Jr
David Edward Tupper
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2009004054A publication Critical patent/MX2009004054A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/38—2-Pyrrolones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2009004054A 2006-10-23 2007-10-22 1,5-difenil-3-bencilamino-1,5-dihidropirrolidin-2-ona como moduladores de receptor de cb1. MX2009004054A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86254006P 2006-10-23 2006-10-23
PCT/US2007/082042 WO2008070306A2 (en) 2006-10-23 2007-10-22 1,5-diphenyl-3-benzylamin0-1,5-dihydr0pyrr0lidin-2-0ne as cb1 receptor modulators

Publications (1)

Publication Number Publication Date
MX2009004054A true MX2009004054A (es) 2009-04-27

Family

ID=39386481

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009004054A MX2009004054A (es) 2006-10-23 2007-10-22 1,5-difenil-3-bencilamino-1,5-dihidropirrolidin-2-ona como moduladores de receptor de cb1.
MX2009004053A MX2009004053A (es) 2006-10-23 2007-10-22 1,5-difenil-3-piridinilamino-1,5-dihidropirrolidin-2-ona como modulador de receptor de cb1.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2009004053A MX2009004053A (es) 2006-10-23 2007-10-22 1,5-difenil-3-piridinilamino-1,5-dihidropirrolidin-2-ona como modulador de receptor de cb1.

Country Status (23)

Country Link
US (2) US8168659B2 (enExample)
EP (2) EP2094684B1 (enExample)
JP (2) JP5331001B2 (enExample)
KR (2) KR101088236B1 (enExample)
CN (2) CN101528733B (enExample)
AR (1) AR063497A1 (enExample)
AT (1) ATE492543T1 (enExample)
AU (1) AU2007329808B2 (enExample)
BR (1) BRPI0717347A2 (enExample)
CA (2) CA2667372C (enExample)
CL (1) CL2007003002A1 (enExample)
CY (1) CY1111140T1 (enExample)
DE (1) DE602007011495D1 (enExample)
DK (2) DK2099784T3 (enExample)
EA (2) EA015175B1 (enExample)
ES (2) ES2356025T3 (enExample)
MX (2) MX2009004054A (enExample)
PE (1) PE20080926A1 (enExample)
PL (2) PL2094684T3 (enExample)
PT (2) PT2094684E (enExample)
SI (2) SI2099784T1 (enExample)
TW (1) TW200825067A (enExample)
WO (2) WO2008070305A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200825067A (en) * 2006-10-23 2008-06-16 Lilly Co Eli CB1 compounds
AU2009238444B2 (en) * 2008-04-22 2013-08-29 Eli Lilly And Company 1,5-diphenyl-pyrrolidin-2-one compounds as CB-1 ligands
ES2390560T3 (es) * 2008-04-22 2012-11-14 Eli Lilly And Company Compuestos de 1,5-difenil-pirrolidin-2-ona como ligandos CB-1
WO2010057000A2 (en) * 2008-11-13 2010-05-20 The Trustees Of Columbia University In The City Of New York Neuraminidase inhibitors and uses thereof
ITTO20110641A1 (it) * 2010-07-15 2012-01-16 Oleg Iliich Epshtein Composizioni farmaceutiche e metodi di trattamento
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
US20240158384A1 (en) * 2020-12-14 2024-05-16 The Board Of Trustees Of The Leland Stanford Junior University Cb2 receptor agonists
WO2023205180A1 (en) 2022-04-19 2023-10-26 Nurix Therapeutics, Inc. Biomarkers for cbl, and compositions and methods for their use
WO2023250097A1 (en) 2022-06-22 2023-12-28 Nurix Therapeutics, Inc. Combination therapies with cbl-b inhibitor compounds and antiemetic agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200533657A (en) * 2004-02-17 2005-10-16 Esteve Labor Dr Substituted pyrazoline compounds, their preparation and use as medicaments
DK1725536T3 (da) * 2004-02-19 2009-02-16 Solvay Pharm Bv Imidazolin-derivater med CB1-antagonistisk aktivitet
US20060035245A1 (en) * 2004-04-20 2006-02-16 Ason Brandon L Modulators of enzymatic nucleic acid elements mobilization
WO2007020502A2 (en) 2005-08-16 2007-02-22 Pharmacia & Upjohn Company Llc Cannabinoid receptor ligands and uses thereof
TW200825067A (en) * 2006-10-23 2008-06-16 Lilly Co Eli CB1 compounds

Also Published As

Publication number Publication date
CL2007003002A1 (es) 2008-06-06
AU2007329807A1 (en) 2008-06-12
KR101088236B1 (ko) 2011-11-30
US20100016375A1 (en) 2010-01-21
WO2008070305A2 (en) 2008-06-12
CN101528732A (zh) 2009-09-09
JP2010507589A (ja) 2010-03-11
EP2099784A2 (en) 2009-09-16
CA2667210C (en) 2013-09-24
CY1111140T1 (el) 2015-06-11
WO2008070305A3 (en) 2008-08-28
EP2094684A2 (en) 2009-09-02
EP2099784B1 (en) 2012-12-12
PL2099784T3 (pl) 2013-05-31
SI2099784T1 (sl) 2013-02-28
PT2099784E (pt) 2013-01-04
SI2094684T1 (sl) 2011-04-29
KR20090069316A (ko) 2009-06-30
AU2007329808A1 (en) 2008-06-12
MX2009004053A (es) 2009-04-27
TW200825067A (en) 2008-06-16
EA015175B1 (ru) 2011-06-30
EA015745B1 (ru) 2011-10-31
PL2094684T3 (pl) 2011-05-31
CA2667210A1 (en) 2008-06-12
AU2007329808B2 (en) 2013-11-07
CA2667372A1 (en) 2008-06-12
ATE492543T1 (de) 2011-01-15
CN101528733A (zh) 2009-09-09
US8168659B2 (en) 2012-05-01
KR101088229B1 (ko) 2011-11-30
PT2094684E (pt) 2011-01-28
CN101528733B (zh) 2013-10-16
PE20080926A1 (es) 2008-07-19
CN101528732B (zh) 2013-04-03
AR063497A1 (es) 2009-01-28
CA2667372C (en) 2013-09-03
US20090275618A1 (en) 2009-11-05
EA200970405A1 (ru) 2009-12-30
DK2099784T3 (da) 2013-01-14
EA200970404A1 (ru) 2009-10-30
WO2008070306A2 (en) 2008-06-12
WO2008070306A3 (en) 2008-07-31
BRPI0717347A2 (pt) 2014-01-14
JP5331001B2 (ja) 2013-10-30
ES2356025T3 (es) 2011-04-04
JP5331002B2 (ja) 2013-10-30
EP2094684B1 (en) 2010-12-22
DE602007011495D1 (de) 2011-02-03
US7998985B2 (en) 2011-08-16
KR20090071613A (ko) 2009-07-01
ES2398388T3 (es) 2013-03-15
DK2094684T3 (da) 2011-03-14
JP2010507590A (ja) 2010-03-11

Similar Documents

Publication Publication Date Title
MX2009004053A (es) 1,5-difenil-3-piridinilamino-1,5-dihidropirrolidin-2-ona como modulador de receptor de cb1.
MX2009005252A (es) Aminopirrolidinas como antagonistas del receptor de quimiocina.
WO2007133802A3 (en) Pharmaceutical formulations of pimavanserin
TW200640867A (en) Pyridine-3-carboxamide derivatives as CB1 inverse agonists
CL2012000707A1 (es) Compuestos derivados de [5-(pirrolo[1,2-c][1.2.3]triazin-7-il)tetrahidrofuran-2-il]metanol; composición farmacéutica; y su uso para el tratamiento de la hepatitis c.
MY150518A (en) Substituted gamma lactams as therapeutic agents
GB0812642D0 (en) Compounds
MX2010009646A (es) Agentes terapeuticos antivirales.
IL193479A0 (en) Modulators of muscarinic receptors
MY153915A (en) Organic compounds
MX2012008049A (es) Compuestos heterociclicos triciclicos, composiciones y metodos de uso de los mismos,.
EP3542629A3 (en) Dithiol compounds, derivatives, and uses therefor
MY146924A (en) Substituted imidazoheterocycles
CY1113734T1 (el) Χημικες ενωσεις
WO2008040649A3 (en) Pyrazine-2-carboxamide derivatives as cb2 receptor modulators
MX2007011023A (es) 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3.
TW200738644A (en) Substituted imidazoles
IN2012DN02556A (enExample)
TW200736233A (en) Cyclohexyl piperazinyl methanone derivatives
TW200942535A (en) Novel compounds as cannabinoid receptor ligands
MX2009000169A (es) Derivados de purinona como agonistas de hm74a.
DE602007006961D1 (de) Cgrp-rezeptorantagonisten
PH12013502616A1 (en) Cyclopropyl amide derivatives 978
MX2011012993A (es) Bencimidazoles, benzotiazoles y benzoxazoles, sustituidos.
MX2012004264A (es) Derivados de sulfoxidos para el tratamiento de tumores.

Legal Events

Date Code Title Description
FG Grant or registration